Full Press Release Details
DUBLIN,July 28, 2025/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2025 financial results and provide a business update after market close onTuesday, August 12, 2025. An accompanying conference call and simultaneous webcast will be hosted at5:00 pm ET(2:00 pm PT/9:00 pm GMT) that day.
Conference Call Information
To participate in the live call by telephone, please pre-registerhere. Those interested in listening to the conference call live via the internet may do so byclicking hereor visiting theEvents and Presentationpage under the Investors Section onTheravance Biopharma's website.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days throughSeptember 11, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliverMedicines that Make a Difference®in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI®(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visitwww.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI®is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.